These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 21303730)

  • 1. Cross-sectional prevalence of metabolic syndrome in Korean patients with schizophrenia.
    Kang SH; Kim KH; Kang GY; Lee KH; Kim KK; Soh M; Ahn KJ; Kim SH; Lee JI
    Schizophr Res; 2011 May; 128(1-3):179-81. PubMed ID: 21303730
    [No Abstract]   [Full Text] [Related]  

  • 2. The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia.
    Lee NY; Roh MS; Kim SH; Jung DC; Yu HY; Sung KH; Chung IW; Youn T; Kang UG; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2013 Mar; 28(2):71-9. PubMed ID: 23211493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
    Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
    Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study.
    Bai YM; Chen TT; Yang WS; Chi YC; Lin CC; Liou YJ; Wang YC; Su TP; Chou P; Chen JY
    Schizophr Res; 2009 Jun; 111(1-3):1-8. PubMed ID: 19409756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings.
    Enez Darcin A; Yalcin Cavus S; Dilbaz N; Kaya H; Dogan E
    Schizophr Res; 2015 Aug; 166(1-3):201-6. PubMed ID: 26004686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population.
    Lee NY; Kim SH; Cho B; Lee YJ; Chang JS; Kang UG; Kim YS; Ahn YM
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1243-9. PubMed ID: 20599461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linkage of cognitive impairments with metabolic disorders in schizophrenia.
    Nasrallah HA
    Am J Psychiatry; 2010 Oct; 167(10):1155-7. PubMed ID: 20889659
    [No Abstract]   [Full Text] [Related]  

  • 8. Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era.
    Basu A; Meltzer HY
    Schizophr Res; 2006 Sep; 86(1-3):99-109. PubMed ID: 16753284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic syndrome and cardiovascular risk among patients with schizophrenia receiving antipsychotics in Malaysia.
    Said MA; Sulaiman AH; Habil MH; Das S; Bakar AK; Yusoff RM; Loo TH; Bakar SA
    Singapore Med J; 2012 Dec; 53(12):801-7. PubMed ID: 23268153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents--a cross-sectional study.
    Kagal UA; Torgal SS; Patil NM; Malleshappa A
    J Pharm Pract; 2012 Jun; 25(3):368-73. PubMed ID: 22551560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications.
    Jerrell JM; McIntyre RS; Tripathi A
    Clin Schizophr Relat Psychoses; 2010 Oct; 4(3):161-8. PubMed ID: 20880826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance.
    Moeller KE; Rigler SK; Mayorga A; Nazir N; Shireman TI
    Schizophr Res; 2011 Mar; 126(1-3):117-23. PubMed ID: 21168994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia.
    Padmavati R; McCreadie RG; Tirupati S
    Schizophr Res; 2010 Aug; 121(1-3):199-202. PubMed ID: 20538429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia.
    Said MA; Hatim A; Habil MH; Zafidah W; Haslina MY; Badiah Y; Ramli MA; Ananjit S; Sapini Y; Shah M; Mahmud B; Bulgiba A; Hairi NN
    Prev Med; 2013; 57 Suppl():S50-3. PubMed ID: 23337566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology.
    De Hert M; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; Falissard B
    Int J Methods Psychiatr Res; 2010 Dec; 19(4):195-210. PubMed ID: 20683849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between metabolic syndrome and cognition in patients with schizophrenia.
    Lindenmayer JP; Khan A; Kaushik S; Thanju A; Praveen R; Hoffman L; Cherath L; Valdez G; Wance D
    Schizophr Res; 2012 Dec; 142(1-3):171-6. PubMed ID: 23106932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study.
    Arango C; Bobes J; Aranda P; Carmena R; Garcia-Garcia M; Rejas J;
    Schizophr Res; 2008 Sep; 104(1-3):1-12. PubMed ID: 18606526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year.
    Schorr SG; Slooff CJ; Bruggeman R; Taxis K
    J Psychiatr Res; 2009 Sep; 43(13):1106-11. PubMed ID: 19398113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome (MetS) in Lebanese patients with schizophrenia receiving atypical antipsychotic drugs.
    Bou Khalil R; Rohayem J; Abou Said N; El Chammay R; Haddad R; Richa S
    Asian J Psychiatr; 2013 Feb; 6(1):88-9. PubMed ID: 23380330
    [No Abstract]   [Full Text] [Related]  

  • 20. Diabetes prevalence estimates in schizophrenia and risk factor assessment.
    Argo T; Carnahan R; Barnett M; Holman TL; Perry PJ
    Ann Clin Psychiatry; 2011 May; 23(2):117-24. PubMed ID: 21547272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.